An open-label, randomized, Phase IIIb trial evaluating the efficacy and safety of standard of care +/- continuous R435(bevacizumab) treatment beyond progression of disease (PD) in patients with advanced non-squamous non-small cell lung cancer (NSCLC) after first (1st)-line treatment with bevacizumab plus a platinum doublet-containing chemotherapy

INTERVENTION: investigational material(s) Generic name etc : bevacizumab INN of investigational material : bevacizumab Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material : 15 mg/kg i.v. CONDITION: non‐squamous non‐small cell lung cancer PRIMARY OUTCOME: ‐To assess the efficacy of continuous R435 treatment beyond PD1 as measured by overall survival(OS).; ‐To assess the safety of R435 treatment across multiple lines of treatment. INCLUSION CRITERIA: ‐Age >= 18 years. ‐Sex:Both ‐Ability to comply with the protocol. ‐Histologically or cytologically confirmed non‐squamous NSCLC ‐At least 1 unidimensionally measurable lesion meeting RECIST (v.1.1) criteria. ‐Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0‐2.